Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 253
Filtrar
1.
Einstein (Sao Paulo) ; 22: eAO0627, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39140572

RESUMEN

OBJECTIVE: This study aimed to evaluate inflammatory biomarkers in patients undergoing peritoneal dialysis and investigate their association with all-cause mortality or transfer to hemodialysis. METHODS: This prospective cohort study included 43 patients undergoing peritoneal dialysis. Plasma levels of cytokines were measured using flow cytometry and capture enzyme-linked immunosorbent assay. Biomarkers were categorized based on their respective median values. Survival analysis was conducted using the Kaplan-Meier estimator, considering two outcomes: all-cause mortality and transfer to hemodialysis. RESULTS: After adjusting for confounding factors, plasma levels above the median of the levels of CCL2 and plasma, as well as below the median of TNF-α, and the median of dialysate IL-17 levels, were associated with an increased risk of experiencing the specified outcomes after approximately 16 months of follow-up. CONCLUSION: These findings suggest that inflammatory biomarkers may be a valuable tool for predicting all-cause mortality and transfer to hemodialysis in patients undergoing peritoneal dialysis.


Asunto(s)
Biomarcadores , Inflamación , Diálisis Peritoneal , Humanos , Diálisis Peritoneal/mortalidad , Masculino , Femenino , Persona de Mediana Edad , Biomarcadores/sangre , Estudios Prospectivos , Inflamación/sangre , Inflamación/mortalidad , Anciano , Estimación de Kaplan-Meier , Ensayo de Inmunoadsorción Enzimática , Fallo Renal Crónico/mortalidad , Fallo Renal Crónico/terapia , Fallo Renal Crónico/sangre , Adulto , Citocinas/sangre , Factor de Necrosis Tumoral alfa/sangre , Factor de Necrosis Tumoral alfa/análisis , Quimiocina CCL2/sangre , Quimiocina CCL2/análisis , Diálisis Renal/mortalidad , Factores de Riesgo , Interleucina-17/sangre , Causas de Muerte , Citometría de Flujo
2.
Ther Apher Dial ; 28(6): 880-885, 2024 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-38845452

RESUMEN

INTRODUCTION: Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are markers of systemic inflammatory status. The relationship between NLR, PLR, and mortality is controversial among hemodialysis (HD) patients. OBJECTIVE: Evaluate NLR and PLR in the prediction of mortality in chronic HD patients. MATERIALS AND METHODS: We analyzed 130 patients with a follow-up for 66 months. Four groups were established according to NLR-PLR values. Kaplan-Meier curves and Cox proportional hazards analysis were used. RESULTS: NLR-PLR correlated positively with C-reactive protein. Cox regression analysis for overall mortality among the four groups included age (HR 1.027, 95% CI 1.003-1.053) and albumin (HR 0.25, 95% CI 0.073-0.85). For cardiovascular (CV) mortality only pulse pressure differential (PPD) was included (HR 1.033; 95% CI 1.014-1.052). Low NLRs and high PLRs were associated with CV mortality (Log Rank test, p = 0.033). CONCLUSIONS: Low NLRs and high PLRs predict the risk of CV mortality among HD patients.


Asunto(s)
Inflamación , Linfocitos , Neutrófilos , Diálisis Renal , Humanos , Diálisis Renal/mortalidad , Masculino , Femenino , México , Persona de Mediana Edad , Inflamación/sangre , Anciano , Plaquetas , Enfermedades Cardiovasculares/mortalidad , Recuento de Plaquetas , Proteína C-Reactiva/metabolismo , Proteína C-Reactiva/análisis , Recuento de Linfocitos , Estudios de Seguimiento , Biomarcadores/sangre , Estudios Retrospectivos , Fallo Renal Crónico/terapia , Fallo Renal Crónico/mortalidad , Fallo Renal Crónico/sangre
3.
Ann Med ; 56(1): 2343890, 2024 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-38738416

RESUMEN

BACKGROUND: The Covid-19 pandemic has affected patients with end-stage kidney disease (ESKD). Whether dialysis parameters have a prognostic value in ESKD patients with Covid-19 remains unclear. MATERIALS AND METHODS: We retrospectively evaluated clinical characteristics, blood pressure (BP) and dialysis parameters in ESKD patients undergoing maintenance outpatient hemodialysis, with (Covid-ESKD) and without (No-Covid-ESKD) Covid-19, at four Brazilian hemodialysis facilities. The Covid-ESKD (n = 107; 54% females; 60.8 ± 17.7 years) and No-Covid-ESKD (n = 107; 62% females; 58.4 ± 14.6 years) groups were matched by calendar time. The average BP and dialysis parameters were calculated during the pre-infection, acute infection, and post-infection periods. The main outcomes were Covid-19 hospitalization and all-cause mortality. RESULTS: Covid-ESKD patients had greater intradialytic and postdialysis systolic BP and lower predialysis weight, postdialysis weight, ultrafiltration rate, and interdialytic weight gain during acute-illness compared to 1-week-before-illness, while these changes were not observed in No-Covid-ESKD patients. After 286 days of follow-up (range, 276-591), there were 18 Covid-19-related hospitalizations and 28 deaths among Covid-ESKD patients. Multivariable logistic regression analysis showed that increases in predialysis systolic BP from 1-week-before-illness to acute-illness (OR, 95%CI = 1.06, 1.02-1.10; p = .004) and Covid-19 vaccination (OR, 95%CI = 0.16, 0.04-0.69; p = .014) were associated with hospitalization in Covid-ESKD patients. Multivariable Cox-regression analysis showed that Covid-19-related hospitalization (HR, 95%CI = 5.17, 2.07-12.96; p < .001) and age (HR, 95%CI = 1.05, 1.01-1.08; p = .008) were independent predictors of all-cause mortality in Covid-ESKD patients. CONCLUSION: Acute Covid-19 illness is associated with variations in dialysis parameters of volume status in patients with ESKD. Furthermore, increases in predialysis BP during acute Covid-19 illness are associated with an adverse prognosis in Covid-ESKD patients.


Dialysis parameters were influenced by SARS-CoV-2 infection and may have prognostic value in patients with Covid-19.Increases in blood pressure during acute Covid-19 illness and the lack of vaccination for Covid-19 were predictors of hospitalization for Covid-19.Hospitalization for Covid-19 and age were independent risk factors for all-cause death.


Asunto(s)
COVID-19 , Fallo Renal Crónico , Diálisis Renal , SARS-CoV-2 , Humanos , COVID-19/complicaciones , COVID-19/mortalidad , COVID-19/epidemiología , COVID-19/terapia , Femenino , Persona de Mediana Edad , Masculino , Fallo Renal Crónico/terapia , Fallo Renal Crónico/complicaciones , Fallo Renal Crónico/mortalidad , Fallo Renal Crónico/epidemiología , Diálisis Renal/estadística & datos numéricos , Estudios Retrospectivos , Pronóstico , Anciano , Brasil/epidemiología , Adulto , Hospitalización/estadística & datos numéricos , Presión Sanguínea
4.
Lupus ; 33(7): 762-768, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38569651

RESUMEN

INTRODUCTION: Although RT has improved the survival of the population with ESRD due to all causes, renal outcomes in SLE are controversial. The objective of this study is to describe the characteristics and evolution of the patients and the kidney transplant in LN, and compare it with patients transplanted for other causes. MATERIALS AND METHODS: Retrospective, observational, analytical, single-center study in which records of patients undergoing nephrotransplantation for LN were analyzed. They were compared with a group of patients transplanted at the same center for other causes of ESRD. RESULTS: 41 patients with kidney transplant due to SLE and 89 transplanted due to other causes of ESRD were registered. Graft loss occurred in 12 (29.26%) patients with LN and 34 (38.2%) patients in the comparison group (p = .428). Only one case (4.8%) presented reactivation of the LN in the graft, without graft loss. Median graft survival was 73.1 months in the LN group and 66.3 months in the comparison group (p = .221). A total of 8 (19.5%) patients with LN and 11 (12.4%) without LN died (p = .42), with infections being the main cause in both groups. There were no statistically significant differences between groups in graft and patient survival. In a sub-analysis of 28 patients with LN with aPL study, 4 thrombotic events were observed, in 3 different patients, in the aPL-positive group. There were no statistically significant differences in terms of causes of graft loss and graft survival (positive aFL 75.7 months vs negative aFL 72.7 months, p= .96). There were also no differences in mortality between the groups (p = .61). CONCLUSION: Patients transplanted for LN did not differ from the control population in terms of graft and patient survival. Infections were the main cause of death, so prophylaxis and vaccination continue to be a fundamental pillar in the prevention of infections in immunocompromised patients.


Asunto(s)
Supervivencia de Injerto , Fallo Renal Crónico , Trasplante de Riñón , Nefritis Lúpica , Humanos , Estudios Retrospectivos , Femenino , Nefritis Lúpica/cirugía , Nefritis Lúpica/mortalidad , Nefritis Lúpica/complicaciones , Adulto , Masculino , Argentina/epidemiología , Fallo Renal Crónico/cirugía , Fallo Renal Crónico/mortalidad , Persona de Mediana Edad , Pronóstico , Adulto Joven , Rechazo de Injerto , Resultado del Tratamiento
5.
Int Urol Nephrol ; 56(9): 3013-3022, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38578392

RESUMEN

PURPOSE: Brazil has one of the world's highest numbers of patients on hemodialysis (HD). Most dialysis centers are private and perform HD for patients with private and public health insurance. We compared 1-year survival between patients initiating chronic HD with public and private health insurance. METHODS: This is an HD register-based retrospective cohort. Adult patients starting HD from January 2011 to December 2021 were included. Survival analysis was stratified according to the period entered in the HD register. Multivariate Cox regression focused on 1-year survival differences between private and public patients. RESULTS: In the final sample (n = 5114), 68.5% of participants had public and 31.3% to private health insurance, with overall 1-year survival of 92.8% and 89.9%, respectively (p = 0.002). Crude analysis showed a slightly higher survival rate among patients with public health insurance than those with private health insurance (91 vs. 87%, p = 0.030) in the first period (2019-21). However, the adjusted hazard ratio (HR) did not remain significantly higher for patients with private health insurance compared to those with public health insurance (HR = 1.07; 95% CI 0.80-1.41; p = 0.651), even after propensity score matching of the groups by several baseline features. CONCLUSION: Brazilian chronic HD patients funded by either private health plans or the public system have a similar 1-year mortality risk after controlling for several sociodemographic and clinical parameters.


Asunto(s)
Seguro de Salud , Sector Privado , Sistema de Registros , Diálisis Renal , Humanos , Brasil/epidemiología , Masculino , Femenino , Persona de Mediana Edad , Seguro de Salud/estadística & datos numéricos , Estudios Retrospectivos , Tasa de Supervivencia , Anciano , Fallo Renal Crónico/terapia , Fallo Renal Crónico/mortalidad , Adulto , Factores de Tiempo , Sector Público , Estudios de Cohortes
6.
Semin Dial ; 37(3): 228-233, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38099410

RESUMEN

BACKGROUND: The nutritional status of incident patients on peritoneal dialysis (PD) has been associated with survival outcomes. Bioimpedanciometry (BCM) enables to establish a nutritional diagnosis, the volume status, and correlates these findings with survival. METHODS: This study used a retrospective multicenter historical cohort. RESULTS: In this study, which included 420 incident patients on peritoneal dialysis with a 5-year follow-up, a cumulative incidence of major adverse cardiovascular events (MACE) of 28.8% was found, being higher in the diabetic population at 36.8%. In regard to the nutritional status in this population, it was found that approximately 44% had altered nutritional status; 34% were found to be in sarcopenia; 6.7% sarcopenic obesity; and 2.8% in obesity (p < 0.001). In the survival analysis, a lower probability of survival was found in patients with overhydration (OH) greater than 3 L (p < 0.001) and in patients with altered nutritional status due to sarcopenia, sarcopenic obesity, and obesity (p 0.016). According to survival in the subgroup of the diabetic population, a lower probability of survival was found in this group of patients (p: 0.011). The overall mortality of the study population was 18%, being higher in the first 2 years, with the most important causes of mortality being cardiovascular. Of the deceased population, 51% were diabetic patients (p: 0.012). CONCLUSION: In incident patients on peritoneal dialysis, sarcopenic obesity, sarcopenia, overhydration status determined by BCM, and having a diagnosis of diabetes are related to a lower probability of survival; MACE outcomes are more frequent in the diabetic population.


Asunto(s)
Enfermedades Cardiovasculares , Fallo Renal Crónico , Estado Nutricional , Diálisis Peritoneal , Humanos , Masculino , Femenino , Enfermedades Cardiovasculares/mortalidad , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/etiología , Persona de Mediana Edad , Estudios Retrospectivos , Incidencia , Fallo Renal Crónico/terapia , Fallo Renal Crónico/mortalidad , Fallo Renal Crónico/complicaciones , Colombia/epidemiología , Anciano , Adulto , Tasa de Supervivencia , Sarcopenia/epidemiología , Sarcopenia/diagnóstico , Sarcopenia/mortalidad , Sarcopenia/etiología
7.
BMC Nephrol ; 23(1): 77, 2022 02 23.
Artículo en Inglés | MEDLINE | ID: mdl-35196997

RESUMEN

BACKGROUND: Although Brazil has one of the largest populations on haemodialysis (HD) in the world, data regarding patients' characteristics and the variables associated with risk of death are scanty. METHODS: This is a retrospective analysis of all adult patients who initiated on maintenance HD at 23 dialysis centres in Brazil between 2012 and 2017. Patients were censored after 60 months of follow-up or at the end of 2019. RESULTS: A total of 5,081 patients were included in the analysis. The median age was 59 years, 59.4% were men, 37.5% had diabetes as the cause of kidney failure. Almost 70% had a central venous catheter (CVC) as the initial vascular access, about 60% started dialysis in the hospital, and fluid overload (FO) by bioimpedance assessment was seen in 45% of patients. The 60-month survival rate was 51.4%. In the Cox regression analysis, being older (P<0.0001), starting dialysis in the hospital (P=0.016), having diabetes as the cause of kidney failure (P=0.001), high alkaline phosphatase (P=0.005), CVC as first vascular access (P=0.023), and FO (P<0.0001) were associated with higher death risk, whereas higher body mass index (P=0.015), haemoglobin (P=0.004), transferrin saturation (P=0.002), and serum albumin (P<0.0001) were associated with better survival. The same variables, except initial CVC use (P=0.14), were associated with death risk in an analysis of subdistribution proportional hazards ratio including the competing outcomes. CONCLUSIONS: The present study gives an overview of a large HD population in a developing country and identifies the main predictors of mortality, including some potentially modifiable ones, such as unplanned initiation of dialysis in the hospital and fluid overload.


Asunto(s)
Fallo Renal Crónico/mortalidad , Fallo Renal Crónico/terapia , Diálisis Renal/mortalidad , Anciano , Brasil , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Retrospectivos
9.
Rev. cuba. med. mil ; 50(1): e437, 2021. graf
Artículo en Español | LILACS, CUMED | ID: biblio-1289503

RESUMEN

Introducción: Al colocar el catéter venoso central en enfermos de insuficiencia renal crónica durante la hemodiálisis, la prevención es imprescindible para evitar la endocarditis infecciosa. El estafilococo dorado es un germen agresivo, que en enfermos inmunodeprimidos con fenómenos cardioembólicos pulmonares y sistémicos, ocasiona daños a funciones de órganos y sistemas. El fenómeno de fallo multiórganos es una complicación temida. Objetivo: Presentar un caso de endocarditis infecciosa agresiva, en un paciente en hemodiálisis. Caso clínico: Paciente femenina, de 31 años de edad, con diagnóstico de endocarditis infecciosa, con tratamiento oportuno, adecuado y multidisciplinario. Después de una mejoría, pasó a un deterioro marcado, falleció por fallo multiórganos, debido a septicemia y cardioembolismos múltiples. Comentarios: La resistencia de los gérmenes agresivos, se hace más frecuente. La vida de la enferma, inmunodeprimida y manipulada, se sitúa en riesgo significativo con fallo multiórganos(AU)


Introduction: When placing the central venous catheter in patients with chronic renal failure during hemodialysis, prevention is essential to avoid infective endocarditis. Staphylococcus aureus is an aggressive germ, which in immunocompromised patients with pulmonary and systemic cardioembolic phenomena, causes damage to functions of organs and systems. The phenomenon of multi-organ failure is a feared complication. Objective: To present a case of aggressive infective endocarditis in a hemodialysis patient. Clinical case: Female patient, 31 years old, with a diagnosis of infective endocarditis, with timely, adequate and multidisciplinary treatment. After an improvement, he went on to a marked deterioration, died due to multi-organ failure, due to septicemia and multiple cardioembolisms. Comment: The resistance of aggressive germs becomes more frequent. The life of the patient, immunocompromised and manipulated, is at significant risk with multi-organ failure (AU)


Asunto(s)
Humanos , Femenino , Adulto , Diálisis Renal/métodos , Endocarditis , Catéteres Venosos Centrales/efectos adversos , Fallo Renal Crónico/mortalidad , Staphylococcus aureus/patogenicidad
10.
Qual Life Res ; 30(6): 1595-1604, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33454887

RESUMEN

PURPOSE: Despite the advancements in renal replacement therapy, patients with end-stage renal disease face several limitations, with significant impacts on health-related quality of life (HRQoL) and mortality. This study aims to examine associations between quality of life and risk of death in Brazilian patients who underwent dialysis therapy between 2007 and 2015. METHODS: Observational, prospective, non-concurrent cohort study of patients who underwent dialysis therapy at the Brazilian Public Health System (SUS) and were followed up for 8 years. Semi-structured questionnaires interrogating socioeconomic and demographic characteristics, as well as HRQoL measures (36 Item Short-Form Health Survey, SF-36), were employed. The Cox proportional risk model was used to investigate associations between HRQoL and risk of death. RESULTS: Our sample comprised 1162 patients; of these, 884 were on hemodialysis (HD) and 278 on peritoneal dialysis (PD). Among the HD patients, death was associated with the physical (HR: 0.993; 95% CI: 0.989-0.997) and physical summary component (HR: 0.994; 95% CI: 0.989-0.999) domains of HRQoL. Regarding the PD patients, death was associated with the bodily pain (HR: 0.994; 95% CI: 0.990-0.998), mental health (HR: 0.094; 95% CI: 0.990-0.998), emotional problems (HR: 0.993; 95% CI: 0.987-0.998), social functioning (HR: 1.012; 95% CI: 1.002-1.023), physical problems (HR: 0.992; 95% CI: 0.986-0.998) and mental summary component (HR: 0.989; 95% CI: 0.981-0.997) domains of HRQoL. CONCLUSIONS: Our data suggest that early and timely intervention measures aiming to enhance the HRQoL of dialysis patients are an essential component of professional practice and may contribute to improving the management of factors associated with dialysis patients' mortality.


Asunto(s)
Fallo Renal Crónico/mortalidad , Fallo Renal Crónico/psicología , Diálisis Peritoneal/psicología , Calidad de Vida/psicología , Diálisis Renal/psicología , Adolescente , Adulto , Anciano , Brasil , Estudios de Cohortes , Femenino , Humanos , Fallo Renal Crónico/terapia , Masculino , Trastornos Mentales/psicología , Salud Mental , Persona de Mediana Edad , Dolor/etiología , Embarazo , Modelos de Riesgos Proporcionales , Estudios Prospectivos , Encuestas y Cuestionarios , Adulto Joven
11.
Ther Apher Dial ; 25(1): 33-43, 2021 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-32352233

RESUMEN

Expanded hemodialysis (HDx) provides increased clearance of conventional and large middle molecules through innovative medium cutoff (MCO) membranes. However, there is a paucity of real-world data regarding the benefits and safety of HDx. This large observational study evaluated outcomes among patients in Colombia undergoing HDx at a extended dialysis clinical services provider. This was a prospective single cohort study of prevalent patients who were treated with HDx; baseline information was collected from the most recent data before patients were started on HDx. Patients were followed prospectively for 1 year for changes in serum albumin and other laboratory parameters compared with the baseline. Survival, hospitalization and safety were assessed from the start of HDx. A total of 1000 patients were invited to enroll; 992 patients met the inclusion criteria for data analysis and 638 patients completed the year of follow-up. Seventy-four (8%) patients died during 866 patient-years (PY) of follow-up; the mortality rate was 8.54 deaths/100 PY (95% confidence interval [CI], 6.8-10.7). There were 673 hospitalization events with a rate of 0.79 events/PY (95% CI, 0.73-0.85) with 6.91 hospital days/PY (95% CI, 6.74-7.09). The observed variability from baseline and maximum average change in mean serum albumin levels were -1.8% and -3.5%, respectively. No adverse events were related to the MCO membrane. HDx using an MCO membrane maintains stable serum albumin levels and is safe in terms of nonoccurrence of dialyzer related adverse events.


Asunto(s)
Fallo Renal Crónico/terapia , Membranas Artificiales , Diálisis Renal/instrumentación , Biomarcadores/análisis , Colombia/epidemiología , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Fallo Renal Crónico/mortalidad , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Sistema de Registros
12.
West Indian med. j ; West Indian med. j;69(2): 103-108, 2021. tab
Artículo en Inglés | LILACS | ID: biblio-1341879

RESUMEN

ABSTRACT Objective: People receiving dialysis have a high mortality rate due to life-threatening, chronic renal failure. These patients experience the fear of pain and suffering, loneliness and death in the haemodialysis unit. This research aimed at determining the perception of death in people receiving dialysis. Methods: A cross-sectional, descriptive research was conducted under the supervision of the Ministry of Health in public hospitals in the cities of Mersin, Izmir, Antalya, Erzurum, Samsun and Gaziantep. A total 240 patients were treated in the dialysis units of these hospitals. Participants were selected with stratified random sampling. For data collection, a patient information form was prepared by the researcher. Data from the study were analysed with Tukey Honest Significant Difference and one-way ANOVA, using an SPSS version 11.5 software package (Statistical Package for the Social Sciences Windows, IBM Corp., Armonk, NY). The statistical significance level was defined as p < 0.05. Results: People receiving dialysis were found to be in a mildly depressive emotional state and they had death anxiety. Death-related anxiety and depression were more common among the female study participants compared to the male participants. Single patients exhibited higher levels of death anxiety compared to married patients. Conclusion: We recommend a holistic and personalised care to allow people receiving dialysis to express their feelings and to overcome the death anxiety. Further research is needed to improve dignified person-centred care for people receiving dialysis.


Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Persona de Mediana Edad , Diálisis/estadística & datos numéricos , Fallo Renal Crónico/mortalidad , Fallo Renal Crónico/terapia , Factores Socioeconómicos , Estudios Transversales
13.
Cochrane Database Syst Rev ; 12: CD004349, 2020 12 17.
Artículo en Inglés | MEDLINE | ID: mdl-33332584

RESUMEN

BACKGROUND: This is the first update of this review first published in 2009. When treating elevated blood pressure, doctors usually try to achieve a blood pressure target. That target is the blood pressure value below which the optimal clinical benefit is supposedly obtained. "The lower the better" approach that guided the treatment of elevated blood pressure for many years was challenged during the last decade due to lack of evidence from randomised trials supporting that strategy. For that reason, the standard blood pressure target in clinical practice during the last years has been less than 140/90 mm Hg for the general population of patients with elevated blood pressure. However, new trials published in recent years have reintroduced the idea of trying to achieve lower blood pressure targets. Therefore, it is important to know whether the benefits outweigh harms when attempting to achieve targets lower than the standard target. OBJECTIVES: The primary objective was to determine if lower blood pressure targets (any target less than or equal to 135/85 mm Hg) are associated with reduction in mortality and morbidity as compared with standard blood pressure targets (less than or equal to 140/ 90 mm Hg) for the treatment of patients with chronic arterial hypertension. The secondary objectives were: to determine if there is a change in mean achieved systolic blood pressure (SBP) and diastolic blood pressure (DBP associated with "lower targets" as compared with "standard targets" in patients with chronic arterial hypertension; and to determine if there is a change in withdrawals due to adverse events with "lower targets" as compared with "standard targets", in patients with elevated blood pressure. SEARCH METHODS: The Cochrane Hypertension Information Specialist searched the following databases for randomised controlled trials up to May 2019: the Cochrane Hypertension Specialised Register, CENTRAL (2019, Issue 4), Ovid MEDLINE, Ovid Embase, the WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov. We also contacted authors of relevant papers regarding further published and unpublished work. The searches had no language restrictions. SELECTION CRITERIA: Randomised controlled trials (RCTs) comparing patients allocated to lower or to standard blood pressure targets (see above). DATA COLLECTION AND ANALYSIS: Two review authors (JAA, VL) independently assessed the included trials and extracted data. Primary outcomes were total mortality; total serious adverse events; myocardial infarction, stroke, congestive heart failure, end stage renal disease, and other serious adverse events. Secondary outcomes were achieved mean SBP and DBP, withdrawals due to adverse effects, and mean number of antihypertensive drugs used. We assessed the risk of bias of each trial using the Cochrane risk of bias tool and the certainty of the evidence using the GRADE approach.  MAIN RESULTS: This update includes 11 RCTs involving 38,688 participants with a mean follow-up of 3.7 years. This represents 7 new RCTs compared with the original version. At baseline the mean weighted age was 63.1 years and the mean weighted blood pressure was 155/91 mm Hg. Lower targets do not reduce total mortality (risk ratio (RR) 0.95, 95% confidence interval (CI) 0.86 to 1.05; 11 trials, 38,688 participants; high-certainty evidence) and do not reduce total serious adverse events (RR 1.04, 95% CI 0.99 to 1.08; 6 trials, 18,165 participants; moderate-certainty evidence). This means that the benefits of lower targets do not outweigh the harms as compared to standard blood pressure targets. Lower targets may reduce myocardial infarction (RR 0.84, 95% CI 0.73 to 0.96; 6 trials, 18,938 participants, absolute risk reduction (ARR) 0.4%, number needed to treat to benefit (NNTB) 250 over 3.7 years) and congestive heart failure (RR 0.75, 95% CI 0.60 to 0.92; 5 trials, 15,859 participants, ARR 0.6%, NNTB  167 over 3.7 years) (low-certainty for both outcomes). Reduction in myocardial infarction and congestive heart failure was not reflected in total serious adverse events. This may be due to an increase in other serious adverse events (RR 1.44, 95% CI 1.32 to 1.59; 6 trials. 18,938 participants, absolute risk increase (ARI) 3%,  number needed to treat to harm (NNTH) 33 over four years) (low-certainty evidence). Participants assigned to a "lower" target received one additional antihypertensive medication and achieved a significantly lower mean SBP (122.8 mm Hg versus 135.0 mm Hg, and a lower mean DBP (82.0 mm Hg versus 85.2 mm Hg, than those assigned to "standard target". AUTHORS' CONCLUSIONS: For the general population of persons with elevated blood pressure, the benefits of trying to achieve a lower blood pressure target rather than a standard target (≤ 140/90 mm Hg) do not outweigh the harms associated with that intervention. Further research is needed to see if some groups of patients would benefit or be harmed by lower targets. The results of this review are primarily applicable to older people with moderate to high cardiovascular risk. They may not be applicable to other populations.


Asunto(s)
Antihipertensivos/uso terapéutico , Presión Sanguínea/fisiología , Hipertensión/tratamiento farmacológico , Sesgo , Enfermedades Cardiovasculares/mortalidad , Causas de Muerte , Intervalos de Confianza , Diástole/fisiología , Guías como Asunto , Insuficiencia Cardíaca/prevención & control , Humanos , Hipertensión/mortalidad , Fallo Renal Crónico/mortalidad , Persona de Mediana Edad , Infarto del Miocardio/prevención & control , Números Necesarios a Tratar , Ensayos Clínicos Controlados Aleatorios como Asunto , Valores de Referencia , Accidente Cerebrovascular/epidemiología
14.
BMC Nephrol ; 21(1): 502, 2020 11 23.
Artículo en Inglés | MEDLINE | ID: mdl-33228547

RESUMEN

BACKGROUND: optimal management of end-stage renal disease (ESRD) in hemodialysis (HD) patients should be more studied because it is a serious risk factor for mortality, being considered an unquestionable global priority. METHODS: we performed a retrospective cohort study from the Nephrology Service in Brazil evaluating the survival of patients with ESRD in HD during 20 years. Kaplan-Meier method with the Log-Rank and Cox's proportional hazards model explored the association between survival time and demographic factors, quality of treatment and laboratory values. RESULTS: Data from 422 patients were included. The mean survival time was 6.79 ± 0.37. The overall survival rates at first year was 82,3%. The survival time correlated significantly with clinical prognostic factors. Prognostic analyses with the Cox proportional hazards regression model and Kaplan-Meier survival curves further identified that leukocyte count (HR = 2.665, 95% CI: 1.39-5.12), serum iron (HR = 8.396, 95% CI: 2.02-34.96), serum calcium (HR = 4.102, 95% CI: 1.35-12.46) and serum protein (HR = 4.630, 95% CI: 2.07-10.34) as an independent risk factor for the prognosis of survival time, while patients with chronic obstructive pyelonephritis (HR = 0.085, 95% CI: 0.01-0.74), high ferritin values (HR = 0.392, 95% CI: 0.19-0.80), serum phosphorus (HR = 0.290, 95% CI: 0.19-0.61) and serum albumin (HR = 0.230, 95% CI: 0.10-0.54) were less risk to die. CONCLUSION: survival remains low in the early years of ESRD treatment. The present study identified that elevated values of ferritin, serum calcium, phosphorus, albumin, leukocyte, serum protein and serum iron values as a useful prognostic factor for the survival time.


Asunto(s)
Fallo Renal Crónico/mortalidad , Terapia de Reemplazo Renal , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Proteínas Sanguíneas/análisis , Calcio/sangre , Femenino , Humanos , Hierro/sangre , Estimación de Kaplan-Meier , Fallo Renal Crónico/sangre , Fallo Renal Crónico/terapia , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Fósforo/sangre , Pronóstico , Modelos de Riesgos Proporcionales , Insuficiencia Renal Crónica/sangre , Insuficiencia Renal Crónica/mortalidad , Insuficiencia Renal Crónica/terapia , Estudios Retrospectivos , Factores de Riesgo , Albúmina Sérica , Tasa de Supervivencia
15.
Transplantation ; 104(8): e236-e242, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32732842

RESUMEN

BACKGROUND: Proper care of young children in need of kidney transplant (KT) requires many skilled professionals and an expensive hospital structure. Small children have lesser access to KT. METHODS: We describe a strategy performed in Brazil to enable and accelerate KT in children ≤15 kg based on the establishment of one specialized transplant center, focused on small children, and cooperating with distant centers throughout the country. Actions on 3 fronts were implemented: (a) providing excellent medical assistance, (b) coordinating educational activities to disseminate expertise and establish a professional network, and (c) fostering research to promote scientific knowledge. We presented the number and outcomes of small children KT as a result of this strategy. RESULTS: Three hundred forty-six pediatric KTs were performed in the specialized center from 2009 to 2017, being 130 in children ≤15 kg (38%, being 41 children ≤10 kg) and 216 in >15 kg (62%). Patient survival after 1 and 5 years of the transplant was 97% and 95% in the "small children" group, whereas, in the "heavier children" group, it was 99% and 96% (P = 0.923). Regarding graft survival, we observed in the "small children" group, 91% and 87%, whereas in the "heavier children" group, 94% and 87% (P = 0.873). These results are comparable to the literature data. Groups were similar in the incidence of reoperation, vascular thrombosis, posttransplant lymphoproliferative disease, and estimated glomerular filtration rate. CONCLUSIONS: The strategy allowed an improvement in the number of KT in small children with excellent results. We believe this experience may be useful in other locations.


Asunto(s)
Rechazo de Injerto/epidemiología , Hospitales Pediátricos/organización & administración , Fallo Renal Crónico/cirugía , Trasplante de Riñón/estadística & datos numéricos , Tiempo de Tratamiento/organización & administración , Adolescente , Peso Corporal/fisiología , Brasil/epidemiología , Niño , Preescolar , Femenino , Estudios de Seguimiento , Tasa de Filtración Glomerular/fisiología , Rechazo de Injerto/etiología , Rechazo de Injerto/fisiopatología , Supervivencia de Injerto/fisiología , Implementación de Plan de Salud , Accesibilidad a los Servicios de Salud/organización & administración , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Hospitales Pediátricos/estadística & datos numéricos , Humanos , Incidencia , Fallo Renal Crónico/mortalidad , Fallo Renal Crónico/fisiopatología , Trasplante de Riñón/efectos adversos , Masculino , Evaluación de Programas y Proyectos de Salud , Análisis de Supervivencia , Factores de Tiempo , Resultado del Tratamiento
16.
Transplantation ; 104(8): 1746-1751, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32732855

RESUMEN

BACKGROUND: The impact of renal transplantation (RT) in the elderly with many comorbid conditions is a matter of concern. The aim of our study was to assess the impact of RT on the survival of patients older than 60 years compared with those remaining on the waiting list (WL) according to their comorbidities. METHODS: In this multicentric observational retrospective cohort study, we included all patients older than 60 years old admitted on the WL from 01 January 2006 to 31 December 2016. The Charlson comorbidity index (CCI) score was calculated for each patient at inclusion on the WL. Kidney donor risk index was used to assess donor characteristics. RESULTS: One thousand and thirty-six patients were included on the WL of which 371 (36%) received an RT during a median follow-up period of 2.5 (1.4-4.1) years. Patient survival was higher after RT compared to patients remaining on the WL, 87%, 80%, and 72% versus 87%, 55%, and 30% at 1, 3, and 5 years, respectively. After RT survival at 5 years was 37% higher for patients with CCI ≥ 3, and 46% higher in those with CCI < 3, compared with patients remaining on the WL. On univariate and multivariate analysis, patient survival was independently associated with a CCI of ≥3 (hazard ratio 1.62; confidence interval 1.09-2.41; P < 0.02) and the use of calcineurin-based therapy maintenance therapy (hazard ratio 0.53; confidence interval 0.34-0.82; P < 0.004). CONCLUSIONS: Our study showed that RT improved survival in patients older than 60 years even those with high comorbidities. The survival after transplantation was also affected by comorbidities.


Asunto(s)
Fallo Renal Crónico/terapia , Trasplante de Riñón/estadística & datos numéricos , Diálisis Renal/estadística & datos numéricos , Adulto , Factores de Edad , Anciano , Argentina/epidemiología , Causas de Muerte , Comorbilidad , Femenino , Estudios de Seguimiento , Humanos , Fallo Renal Crónico/mortalidad , Masculino , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Estudios Retrospectivos , Análisis de Supervivencia , Resultado del Tratamiento , Listas de Espera/mortalidad
18.
Transplant Proc ; 52(4): 1049-1052, 2020 May.
Artículo en Inglés | MEDLINE | ID: mdl-32217013

RESUMEN

Kidney Donor Profile Index (KDPI), derived from donor characteristics, was developed in the United States in an effort to devise an objective means of assessing donor organ suitability based on predicted graft survival. The objective of this study is to analyze the utility of KDPI to predict renal graft survival in Argentina. We conducted a retrospective national cohort study of adult patients who received a deceased donor renal transplantation in Argentina between January 2008 and December 2017. The graft survival was estimated according to the KDPI stratified by quartiles. A Kaplan-Meier analysis was used to calculate survival. A Cox regression was performed to estimate the probability of graft loss for each quart of the KDPI adjusted by receptor variables (age, diabetes, sex, and dialysis time) and cold ischemia time. In a Kaplan-Meier analysis, the graft survival decreases as the quartile of KDPI increases. Multivariate analysis shows that the increase in KDPI quartile and recipient's characteristics-such as age ≥60 years, diabetes, and dialysis time-were related to the probability of graft loss. In conclusion, the KDPI system could provide a guide to objectively assess the quality of organs offered for transplantation in Argentina.


Asunto(s)
Selección de Donante/métodos , Supervivencia de Injerto , Trasplante de Riñón , Donantes de Tejidos , Adulto , Argentina , Estudios de Cohortes , Isquemia Fría , Femenino , Humanos , Estimación de Kaplan-Meier , Fallo Renal Crónico/mortalidad , Fallo Renal Crónico/cirugía , Trasplante de Riñón/mortalidad , Masculino , Persona de Mediana Edad , Análisis Multivariante , Estudios Retrospectivos , Estados Unidos
19.
Int Health ; 12(2): 142-147, 2020 02 12.
Artículo en Inglés | MEDLINE | ID: mdl-31294777

RESUMEN

BACKGROUND: Understanding the pattern of mortality linked to end stage renal disease (ESRD) is important given the increasing ageing population in low- and middle-income countries. METHODS: We analyzed older patients with ESRD with incident hemodialysis, from January 2012 to August 2017 in one large general hospital in Peru. Individual and health system-related variables were analyzed using Generalized Linear Models (GLM) to estimate their association with in-hospital all-cause mortality. Relative risk (RR) with their 95% confidence intervals (95% CI) were calculated. RESULTS: We evaluated 312 patients; mean age 69 years, 93.6% started hemodialysis with a transient central venous catheter, 1.7% had previous hemodialysis indication and 24.7% died during hospital stay. The mean length of stay was 16.1 days (SD 13.5). In the adjusted multivariate models, we found higher in-hospital mortality among those with encephalopathy (aRR 1.85, 95% CI 1.21-2.82 vs. without encephalopathy) and a lower in-hospital mortality among those with eGFR ≤7 mL/min (aRR 0.45, 95% CI 0.31-0.67 vs. eGFR>7 mL/min). CONCLUSIONS: There is a high in-hospital mortality among older hemodialysis patients in Peru. The presence of uremic encephalopathy was associated with higher mortality and a lower estimated glomerular filtration rate with lower mortality.


Asunto(s)
Mortalidad Hospitalaria , Fallo Renal Crónico/mortalidad , Fallo Renal Crónico/terapia , Diálisis Renal/estadística & datos numéricos , Distribución por Edad , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Perú/epidemiología , Factores de Riesgo
20.
Ann Vasc Surg ; 62: 304-309, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31449952

RESUMEN

BACKGROUND: An arteriovenous fistula (AVF) is the preferred vascular access for long-term hemodialysis. The main disadvantage of AVF is the rate of nonmaturation or unsuccessful use for hemodialysis (FUHD). We described our findings in AVF creation and possible risk factors associated with FUHD. METHODS: This is a retrospective study of AVFs during a 6-year period. Variables collected at the time of creation were demographics, comorbidities, replacement therapy, preoperative laboratory tests, and estimated 6-month mortality on hemodialysis. All AVFs were created in the upper arms. Outcomes were FUHD, cannulation failure, and cumulative survival. Univariate and multivariate analyses were performed to find possible risk factors for FUHD. RESULTS: AVFs were created in 78 patients. Average age was 36.3 years, and 74.4% were male. Mean body mass index was 24.5 kg/m2. The most common etiologies were glomerulopathy (53.6%) and diabetes mellitus (13.4%). Estimated six-month mortality was 4.2%. One patient underwent AVF before hemodialysis (mean dialysis time 2.2 years). Nineteen AVFs were considered FUHD (23.2%). Cannulation failure was 15.9%. AVF 1-year and 3-year survival was 67.8% and 63.5%, respectively. FUHD had higher estimated six-month mortality on hemodialysis, shorter prothrombin time, and lower serum albumin level than successful AVF (univariate analysis) (P < 0.05) Short prothrombin time and albumin were confirmed for FUHD (multivariate analysis). A 3.3-gr/dL serum albumin cutoff point (area under the curve, 0.715; receiver operating characteristic) (P < 0.05) was determined for FUHD. CONCLUSIONS: The population referred for AVF creation possesses different characteristics in our center. Good AVF outcomes can be achieved. Preoperative serum albumin level and prothrombin time could be the possible risk factors associated with unsuccessful AVF use.


Asunto(s)
Derivación Arteriovenosa Quirúrgica/efectos adversos , Fallo Renal Crónico/terapia , Diálisis Renal , Adulto , Anciano , Derivación Arteriovenosa Quirúrgica/mortalidad , Biomarcadores/sangre , Coagulación Sanguínea , Femenino , Humanos , Fallo Renal Crónico/sangre , Fallo Renal Crónico/diagnóstico , Fallo Renal Crónico/mortalidad , Masculino , México , Persona de Mediana Edad , Tiempo de Protrombina , Diálisis Renal/efectos adversos , Diálisis Renal/mortalidad , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Albúmina Sérica Humana/metabolismo , Factores de Tiempo , Insuficiencia del Tratamiento , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA